Clinical significance of SQSTM1/P62 and nuclear factor-κB expression in pancreatic carcinoma

Table 1 Relationships among phosph-P65 expression, P62 expression, and clinicopathological features in pancreatic carcinomas (n = 40)

Clinicopathological feature	n	Phosph-P65			P value1	P62			P value1
		Positive		Negative		Positive		Negative
Gender	40	35		5	1.000	37		3	0.141
Male	24	21		3		21		3
Female	16	14		2		16		0
Age (yr)					0.329				0.806
< 60	24	22		2		22		2
≥ 60	16	13		3		15		1
Pathology type					0.002				0.746
Duct adenocarcinoma	29	27		2		26		3
Adenocarcinoma	9	8		1		9		0
Squamous cell carcinoma	1	0		1		1		0
Acinic cell carcinoma	1	0		1		1		0
T stage					0.885				0.001
T0	0	0		0		0		0
T1	1	1		0		0		1
T2	10	9		1		10		0
T3	29	25		4		27		2
T4	0	0		0		0		0
N stage					0.496				0.608
N0	37	32		5		34		3
N1	3	3		0		3		0
N2	0	0		0		0		0
N3	0	0		0		0		0
M stage					0.702				0.773
M0	39	34		5		36		3
M1	1	1		0		1		0
TNM stage					0.934				0.939
I	11	10		1		10		1
II	28	25		3		26		2
III	0	0		0		0		0
IV	1	1		0		1		0

¹Pearson χ². TNM: Tumor-node-metastasis.

Table 2 Relationships between the positive expression of phosph-P65 and clinicopathological features in pancreatic carcinomas (n = 35)

Clinicopathological feature	n	Phosph-P65		P value1
		+++	++
Gender	35	16	19	0.678
Male	21	9	12
Female	14	7	7
Age (yr)				0.508
< 60	22	11	11
≥ 60	13	5	8
Pathology type				0.181
Duct adenocarcinoma	27	14	13
Adenocarcinoma	8	2	6
T stage				0.027
T0	0	0	0
T1	1	0	1
T2	9	1	8
T3	25	15	10
T4	0	0	0
N stage				0.446
N0	32	14	18
N1	3	2	1
N2	0	0	0
N3	0	0	0
M stage				0.352
M0	34	16	18
M1	1	0	1
TNM stage				0.006
I	11	1	10
II	23	15	8
III	0	0	0
IV	1	0	1

¹Pearson χ². TNM: Tumor-node-metastasis.

Table 3 Relationships between the positive expression of P62 and clinicopathological features in pancreatic carcinoma (n = 37)

Clinicopathologic feature	n	P62		P value1
		+++	++
Gender	37	22	15	0.093
Male	21	10	11
Female	16	12	4
Age (yr)				0.036
< 60	22	10	12
≥ 60	15	12	3
Pathology type				0.310
Duct adenocarcinoma	26	13	13
Adenocarcinoma	9	7	2
Squamous cell carcinoma	1	1	0
Acinic cell carcinoma	1	1	0
T stage				0.967
T0	0	0	0
T1	0	0	0
T2	10	6	4
T3	27	16	11
T4	0	0	0
N stage				0.791
N0	34	20	14
N1	3	2	1
N2	0	0	0
N3	0	0	0
M stage				0.220
M0	36	22	14
M1	1	0	1
TNM stage				0.469
I	10	6	4
II	26	16	10
III	0	0	0
IV	1	0	1

¹Pearson χ². TNM: Tumor-node-metastasis.

Table 4 Correlation between Phospho-P65 and P62 expression in human pancreatic carcinoma tissues (P = 0.462, Spearman rank correlation)

P62	Phospho-P65		Total
	-	+
-	1	2	3
+	4	33	37
Total	5	35	40

Table 5 Relationships between pathology type and clinical features in pancreatic carcinoma with positive phosph-P65 expression (n = 35)

Clinicopathological feature	n	Gender		P value1	Age (yr)		P value1	T stage		P value1
		Male	Female		< 60	≥ 60		T1-T2	T3
Pathology type	35	21	14	0.511	22	13	0.981	10	25	0.799
Duct adenocarcinoma	27	17	10)		17	10		8	19
Adenocarcinoma	8	4	4		5	3		2	6
Squamous cell carcinoma	0	0	0		0	0		0	0
Acinic cell carcinoma	0	0	0		0	0		0	0

¹Pearson χ².

Table 6 Relationships between T stage and clinicopathological features in pancreatic carcinoma with positive P62 expression (n = 37)

Clinicopathological feature	n	Gender		P value1	Age (yr)		P value1	Pathology type				P value1
		Male	Female		< 60	≥ 60		DAC	AC	SCC	ACC
T stage	37	21	16	0.614	22	15	0.476	26	9	1	1	0.365
T1-T2	10	5	5		5	5		7	2	0	1
T3	27	16	11		17	10		19	7	1	0

¹Pearson χ². DAC: Duct adenocarcinoma; AC: Adenocarcinoma; SCC: Squamous cell carcinoma; ACC: Acinic cell carcinoma.